Current studies into retatrutide peptide demonstrate notable outlook for treating obesity and non-insulin dependent diabetes. The peptide, a dual agonist of glucagon-like peptide-1 and GIP, looks to offer improved weight loss and blood sugar regulation compared existing medications. Additional clinical trials are required to fully assess its secure